In order to enable the sound execution of our mission, a scientific strategy which responsive of our goals and reflective of our values, was formulated. To account for feasibility, the existing scientific research base relevant to internationally competitive research in the field of molecular medicine was evaluated at research institutions, which establish the HCEMM. Furthermore, the process included consultation with scientific experts of EMBL to create a strategy that is readily embedded in current trends in molecular life sciences in Europe.
The strategy is based on three thematic pillars (these thematic pillars are organized into divisions) and three cross-cutting horizontal themes. Of further importance, high quality excellent research would be most efficiently (but not exclusively) supported by establishing a matrix of advanced core facilities (ACF) in the HCEMM.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 739593. HCEMM supported by EU Programme: H2020-EU.4.a. – Teaming of excellent research institutions and low performing RDI regions. Project starting date was 1 April 2017.
